| |
 |
 |
 |
 |
 |
 |
 |
December 8, 2003
Japanese
medical-use patent issued for NF B
decoy oligo
-Covering
treatment and preventive drugs for ischemic diseases, organ
transplantions and cancers- |
 |
|
|
AnGes MG today announced the issuance of a Japanese
utility patent (JP3474879) for the treatment of NF B
associated diseases such as ischemic diseases, organ transplantations,
and metastasis/invasion or cachexia of cancers.
Specifically, it claims treatments of "reperfusion disorder
in ischemic diseases, postoperative aggravation from organ transplantations
and surgery, and post PTCA restenosis" and "cancer
metastasis/invasion and cachexia" by NFB
decoy oligo. In addition to the Company's joint R&D with
Goodman Co., Ltd. for a NFB
decoy oligo coating stent, this patent was developed to support
the Company's expansion of the medicine's scope of applications
including cancer, as well as promote the Company's clinical
trial projects relating to NFB
decoy oligo.
Corresponding patents were established abroad to effectively
protect the clinical development globally.
US patent (issued in July 2001) 6262033
Patent pending in Europe
Finally, additional medical use patent applications, such as
atopic dermatitis, psoriasis, and rheumatic arthritis, were
filed subsequent to this patent, to expand the scope of the
clinical applications. |
| Reference |
|
|
|
 Explanation
of specialized terms
1. NF B
(nuclear factor-kappa B)
NFB
is a genetic factor enabling regulation of cytokines and adhesion
factors - related to immunological reactions. Bonding NFB
to a genome causes excessive transcription of immunization-related
genetic expressions. This is why NFB
has been indicated as one of the causes of atopic dermatitis
and rheumatic arthritis.
2. NFB
decoy oligo (NF-B
decoy oligodeoxynucleotide)
A genetic expression features a switch - transcription factor
- bonded to a genome.
A decoy is an artificial gene (also referred to as nucleotide)
in which a "compressed" nucleic acid of the same genetic
sequences as the aforementioned transcriptional factor is artificially
synthesized, which when introduced to the body, neutralizes
those "switches" by preventing their bonding to a
genome, thereby regulating the transcription process.
It is a decoy nucleotide against NFB.
AnGes MG is developing therapeutic agents on the basis of its
properties to treat patients suffering from atopic dermatitis,
rheumatic arthritis, and restenosis - conditions caused by excessive
immunological response.
3. Utility patent
In pharmaceutical industry, the patent for the medicine's scope
of applications is generally called utility patent or medical
patent, which claims a strong right to monopolize manufacture,
sales and import of the medicine for the disease.
There are also composition of matter patent for medicine itself,
process patent for the manufacturing method of medicine and
pharmaceutical patent for the preparation of medicine.
4. Cachexy
Cachexy is pathological dystrophic general prostration caused
by cancer and involves such symptoms as total debilitation,
emaciation, edema of the eyelids or lower limbs, and anemic
pallor. AnGes has verified the effect of NFB
decoy oligo on cachexy improvement in animal tests and inhibitory
effects in metastasis models.
5. Reperfusion
disorder
Blood vessels or internal organs may suffer serious
damage when blood flow resumes after blood vessels had been
clogged from thrombus/arteriosclerosis, or after a temporary
blocking of blood flow during operations or organ transplants
- this condition is called reperfusion disorder.
6. PTCA(Percutaneous Transluminal Coronary
Angioplasty), stent
PTCA is a technology to dilate narrow areas of blood
vessels by using a balloon catheter for occlusive lesions of
coronary artery. It is also referred to as the "balloon
catheter technique" because a balloon is used.
PTCA is an excellent technology, but has a defect rate of approximately
40% occurrence of restenosis, reocclusion of the lesions. In
contrast, a technique in which a stent (mesh tube mainly made
of stainless steel) is implanted in the blood vessels dilated
by PTCA is frequently used in recent years. The rate of restenosis
in this stent therapy is approximately 30%, and drug-coated
stents that are coated with anticancer drugs or immunosupressants
on the surface, are being developed mainly in the U.S. as a
next generation treatment.
AnGes is thus developing a stent coated with NFB
decoy oligo cooperating with Goodman Co., Ltd. |
|
|
